Ventyx Biosciences (NASDAQ:VTYX – Get Rating) had its price objective raised by research analysts at Evercore ISI from $50.00 to $65.00 in a report issued on Thursday, The Fly reports. Evercore ISI's price target would suggest a potential upside of 56.78% from the stock's previous close.

Several other equities research analysts also recently weighed in on VTYX. Morgan Stanley assumed coverage on Ventyx Biosciences in a research report on Thursday, November 17th. They set an "overweight" rating and a $45.00 price target on the stock. The Goldman Sachs Group began coverage on Ventyx Biosciences in a research report on Monday, December 19th. They set a "buy" rating and a $50.00 target price on the stock. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $50.67.

Ventyx Biosciences Stock Performance

Ventyx Biosciences stock opened at $41.46 on Thursday. The business has a fifty day moving average of $31.56 and a two-hundred day moving average of $27.52. Ventyx Biosciences has a twelve month low of $9.50 and a twelve month high of $43.81.

Insiders Place Their Bets

In other news, Director William Richard White sold 33,353 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $35.10, for a total transaction of $1,170,690.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, Director William Richard White sold 33,353 shares of Ventyx Biosciences stock in a transaction that occurred on Monday, January 23rd. The shares were sold at an average price of $35.10, for a total transaction of $1,170,690.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Nsv Partners Iii Lp sold 143,228 shares of Ventyx Biosciences stock in a transaction that occurred on Wednesday, November 30th. The shares were sold at an average price of $29.01, for a total transaction of $4,155,044.28. Following the completion of the sale, the insider now owns 16,745,365 shares of the company's stock, valued at approximately $485,783,038.65. The disclosure for this sale can be found here. Insiders have sold 1,206,646 shares of company stock valued at $36,781,043 in the last ninety days. 49.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Ventyx Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Connective Portfolio Management LLC acquired a new position in shares of Ventyx Biosciences during the fourth quarter worth about $492,000. Moody Aldrich Partners LLC acquired a new stake in shares of Ventyx Biosciences in the fourth quarter valued at approximately $2,599,000. Carnegie Capital Asset Management LLC purchased a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $515,000. Avestar Capital LLC purchased a new position in shares of Ventyx Biosciences during the fourth quarter valued at approximately $212,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Ventyx Biosciences by 60.0% during the third quarter. Bank of New York Mellon Corp now owns 80,445 shares of the company's stock valued at $2,809,000 after buying an additional 30,153 shares during the period. 95.57% of the stock is owned by hedge funds and other institutional investors.

Ventyx Biosciences Company Profile

(Get Rating)

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. Its lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease.

See Also

• Get a free copy of the StockNews.com research report on Ventyx Biosciences (VTYX)
• MarketBeat Week in Review – 1/23- 1/27
• Why Lucid Spiked Nearly 100% In One Day
• Ride These Railroad Stocks for Growth and Income
• ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
• KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for Ventyx Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ventyx Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.